	US 12,133,913 B2
	Methods of treating overactive bladder using trospium
Dennis Giesing, Lee's Summit, MO (US)
Assigned to TARIS Biomedical LLC, Lexington, MA (US)
Filed by TARIS BIOMEDICAL LLC, Lexington, MA (US)
Filed on Aug. 11, 2022, as Appl. No. 17/886,325.
Application 17/886,325 is a continuation of application No. 16/528,032, filed on Jul. 31, 2019, granted, now 11,464,734.
Claims priority of provisional application 62/850,481, filed on May 20, 2019.
Claims priority of provisional application 62/713,414, filed on Aug. 1, 2018.
Prior Publication US 2023/0075003 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/439 (2006.01); A61P 13/10 (2006.01)

CPC A61K 9/0034 (2013.01) [A61K 31/439 (2013.01); A61P 13/10 (2018.01)]

20 Claims

1. A method of treating idiopathic overactive bladder in an individual that has received a prior oral therapy, comprising

i) a first phase comprising continuously administering an effective amount of trospium to the bladder of the individual for at least about 42 days, and

ii) a maintenance phase comprising continuously administering an effective amount of trospium to the bladder of the individual for at least about 42 days,

wherein the maintenance phase is initiated upon symptom reoccurrence following the first phase.